TABLE 2.
All‐causality treatment‐emergent adverse events by preferred term following twice‐daily oral dosing of danuglipron a
| Preferred term | All participants (N = 37) | Placebo (N = 9) | Danuglipron dose | ||
|---|---|---|---|---|---|
| 40 mg BID (N = 10) | 80 mg BID (N = 9) | 120 mg BID (N = 9) | |||
| Nausea | 18 (48.6) | 0 | 6 (60.0) | 8 (88.9) | 4 (44.4) |
| Vomiting | 16 (43.2) | 0 | 5 (50.0) | 6 (66.7) | 5 (55.6) |
| Abdominal discomfort | 13 (35.1) | 0 | 4 (40.0) | 4 (44.4) | 5 (55.6) |
| Diarrhoea | 4 (10.8) | 0 | 1 (10.0) | 2 (22.2) | 1 (11.1) |
| Headache | 4 (10.8) | 1 (11.1) | 2 (20.0) | 1 (11.1) | 0 |
| Decreased appetite | 2 (5.4) | 0 | 0 | 1 (11.1) | 1 (11.1) |
| Dental caries | 2 (5.4) | 1 (11.1) | 0 | 0 | 1 (11.1) |
Note: data are n (%). Participants were counted only once per treatment per event.
Abbreviation: BID, twice daily.
a
Treatment‐emergent adverse events with ≥2 occurrences.